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Not just misshapen red cells
In a 1910 report of an anemic West Indian man, Herrick first described the "peculiar elongated and sickle-shaped" rbcs produced by individuals with sickle cell anemia (1) . Over the next century, evaluation of sickle cell anemia-associated molecular and cellular pathobiology revealed that the polymerization of hemoglobin S and cellular shape change upon deoxygenation were due to a single nucleotide mutation (A to T) in the gene encoding β-globin. The pain crises and organ infarctions that manifest in patients were attributed to a mechanical obstruction of blood flow due to the rigid crescent-shaped cells; however, in 1980 Hebbel and others demonstrated that sickle erythrocytes were excessively adherent to vascular endothelial cells (2).
As a result of this seminal observation, researchers in the 1980s and 1990s were able to define the red cell characteristics, endothelial adhesion molecules, and plasma factors responsible for these phenomena. Patients with sickle cell disease (SCD) have marked leukocytosis, thrombocytosis, markers of inflammation, oxidative stress, and a procoagulant phenotype. Other cells have been implicated in sickle-associated vaso-occlusive events, including neutrophils (3, 4), monocytes (5, 6), platelets (4, 7), invariant NKT lymphocytes (8) , and the endothelium itself (2, 9-11).
Of mice and men: murine SCD models tell a hot story Transgenic mouse models of SCD have redefined the pathophysiology of vasoocclusion. SCD models have been developed monocyte and platelet-neutrophil aggregates have been observed in SCD patients. Recent trials have examined the ability of the P2Y12 inhibitor prasugrel to reduce pain crises (18) , and the αIIb/βIIIa inhibitor eptifibatide is currently being examined to relieve SCD-associated symptoms (19) . Additionally, efficacy of a glycomimetic pan-selectin inhibitor (GMI-1070) is now being tested in SCD patients (20) .
How are multicell interactions conducted in this orchestra?
The complex orchestration that leads to vaso-occlusion in SCD requires one unde- (21) . Basal phosphorylation levels the blockage (Figure 1) , and several cellular molecules and interactions have been implicated in murine vaso-occlusion ( Figure 2 ).
Human sickle rbcs and platelets interact with monocytes and neutrophils, which can be found within heterotypic aggregates (4, 6) . Hemolysis is critical in the vasculopathy of SCD (15), and recent studies demonstrating neutrophil extracellular trap (NET) formation in response to heme further implicate interactions between leukocytes and sickle cells in vaso-occlusion development (16, 17) . Leukocytosis in SCD patients is associated with an increased risk of acute chest syndrome, stroke, and mortality, adding credence to the hypothesis that SCD is a disease of inflammation.
Don't forget the platelet in SCD
Most patients with SCD have a high platelet count that is related, in part, to inflammation and the asplenic state. Just as activated leukocytes have been investigated in SCD, so have activated platelets (4, 7) . Platelets may contribute to vaso-occlusion and stroke in SCD patients due to hemolysis associated with platelet activation via released ADP acting on G proteincoupled purinergic receptor P2Y12 (18) or heme interactions with TLR4 (11). Activated platelets can promote sickle red cell adhesion, form platelet-red cell, plateletneutrophil, and platelet-monocyte aggregates, activate coagulation through CD40 expression, and interact with activated vWF. Platelet aggregates with neutrophils and monocytes result from interactions between platelet P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) on leukocytes and interactions between platelet glycoprotein Ibα (GPIbα) and integrin αM/ β2 on monocytes. High levels of plateletwith varying degrees of severity, exhibiting hemolytic anemia, leukocytosis, markers of inflammation, and activated coagulation. Furthermore, these animal models mimic the pathology of human disease in response to stimuli, including hypoxiareoxygenation, cytokines, LPS, and hemoglobin/heme (12) (13) (14) . Kaul and Hebbel showed that pathological stimuli, such as hypoxia-reoxygenation, resulted in decreased blood flow, enhanced leukocyte rolling, adhesion, emigration, and enhanced oxidant production, strongly supporting the concept that SCD is a disease of inflammation, oxidative stress, and reperfusion/injury physiology (9) . Turhan and Frenette demonstrated that leukocytes mediate TNF-α-induced vasoocclusion, which leads to reduced blood flow and death. Leukocyte-dependent vaso-occlusion was prevented in mice lacking both P-and E-selectins (3). We have shown that treatment with antibodies targeting multiple adhesion molecules, including VCAM-1, ICAM-1, P-selectin, E-selectin, α4β1, αVβ3, vWF, or PECAM-1, inhibits microvascular stasis as assessed with a dorsal skinfold chamber on sickle mice in response to hypoxia-reoxygenation or hemoglobin/heme infusion (11) . Histology of a suspected vascular obstruction in the skin of a transgenic sickle mouse following hypoxia-reoxygenation indicates that multiple cell types are present within
Figure 1
Histology of a venule in the dorsal skin of transgenic sickle mice after 1 hour of hypoxia and 1 hour of reoxygenation. Dorsal skin samples were taken for histological analysis after S+S-Antilles sickle mice were exposed to 1 hour of hypoxia and 1 hour of reoxygenation. Skin samples were fixed overnight in formalin, cut into 5-μm sections, embedded in paraffin, mounted on slides, and stained with hematoxylin and eosin before microscopic examination. The image shows a venule with a suspected vascular obstruction. White arrowheads point to leukocytes that appear to be adherent to the vascular endothelium, and white arrows point to misshapen rbcs inside the venule. Reprinted with permission from American Journal of Hematology (24) .
before targeting AKT2 for SCD therapy. Patients with SCD are prone to infection, and inhibition of AKT could worsen this by inactivating host-defending neutrophils. Mice lacking Akt2 present with hyperinsulinemia and diabetes-like syndrome, because AKT2 is highly expressed in insulin-responsive tissues (22) . Previously, the observed phosphorylation of nuclear AKT in livers of sickle mice overexpressing heme oxygenase-1 (HO-1) or after treatment with inhaled CO suggested an antiinflammatory role for AKT (23) . The observed AKT phosphorylation induced by HO-1 and CO could possibly be due to selective activation of AKT isoforms AKT1 or AKT3.
Ultimately, the primacy of hemoglobin S, hemolysis, oxidative stress, and subsequent inflammation in SCD pathogenesis rules any approaches to limiting SCDassociated damage. Strategies aimed at minimizing hemoglobin S, through gene therapy or stem cell transplantation, and minimizing hemoglobin S polymerization, of AKT isoforms were markedly increased in neutrophils and platelets isolated from SCD patients. Inhibition of AKT2 reduced heterotypic aggregation of patients' neutrophils and platelets in vitro and diminished neutrophil adhesion and neutrophil-platelet aggregation in SCD mice, thereby improving blood flow rates. These results provide important evidence that neutrophil-associated AKT2 regulates αM/β2 integrin (CD18/CD11b) function and promotes neutrophil recruitment and neutrophil-platelet interactions in response to thromboinflammatory conditions such as SCD.
This elegant study by Li and colleagues does not, however, answer the question of who conducts the orchestra of vaso-occlusion, but it provides important insights into the players. Furthermore, the study does not reconcile previous investigations that have demonstrated the importance of P-selectin in vaso-occlusion. Is AKT2 the bad sibling? Caution should be used
Figure 2
Conceptual model of molecular and cellular interactions that influence the development of vaso-occlusion in SCD mice. Blockade or deletion of factors, including P-and E-selectin, VCAM-1, ICAM-1, and PECAM-1, which are associated with endothelial cell activation, prevents vaso-occlusion in SCD mice. Furthermore, molecules present on platelets, reticulocytes, sickled rbcs, neutrophils, and monocytes have been implicated in the development of murine SCD-associated vaso-occlusion. Li and colleagues (21) have determined that neutrophil AKT2 may be required for vaso-occlusion. Despite the identification of a myriad of molecules and cell types that mediate vaso-occlusion, the timing of events and the initiating signals remain to be determined.
by increasing hemoglobin F, are the best hopes for minimizing SCD patient morbidity and mortality. Approaches geared toward dealing with hemolysis, either by scavenging hemoglobin/heme or detoxifying heme through HO-1, may limit the inflammation. Other strategies for ameliorating SCD, including antiinflammatories, vasoprotectants, and antithrombotics, will be useful; however, these approaches could compromise host defenses. Herrick never could have imagined over 100 years ago the complexity of the pathobiology of the peculiar-shaped cells that he observed. Hopefully, the use of nanotechnology to provide a "miniature submarine" to explore the vasculature of SCD individuals will be on the horizon to provide us with a better understanding of vaso-occlusion.
